Opioid Use Disorder Pharmacotherapy
Cross-source consensus on Opioid Use Disorder Pharmacotherapy from 1 sources and 5 claims.
1 sources · 5 claims
Uses
How it works
Benefits
Highlighted claims
- Every opioid use disorder treatment model involved pharmacy staff working within multidisciplinary teams alongside physicians, nurses, social workers, and community organisation staff. — Harm reduction and pharmacy practice: a scoping review of services for people who use drugs provided by pharmacy staff
- Buprenorphine was presented as a harm reduction tool for patients not aiming for abstinence and as part of low-threshold care. — Harm reduction and pharmacy practice: a scoping review of services for people who use drugs provided by pharmacy staff
- In one multidisciplinary inpatient model, patients who received team consultation had shorter hospital stays and lower 30-day readmission rates than those who did not. — Harm reduction and pharmacy practice: a scoping review of services for people who use drugs provided by pharmacy staff
- Pharmacy-based opioid use disorder models were generally low-barrier and included optional non-punitive urine drug screening in at least one programme. — Harm reduction and pharmacy practice: a scoping review of services for people who use drugs provided by pharmacy staff
- Pharmacy-based opioid use disorder programmes increased access to buprenorphine and supported treatment adherence. — Harm reduction and pharmacy practice: a scoping review of services for people who use drugs provided by pharmacy staff